Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05307705 · ClinicalTrials.gov registry record · Phase 1
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
A Phase 1 study of Breast Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 193
- Enrollment target
- 20
- Study locations
NCT05307705: Active Phase 1 study of Breast Cancer, sponsored by Eli Lilly and Company.
NCT05307705 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 193 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05307705, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 193 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Primary Outcome
Number of patients with DLTs
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Abemaciclib
- DRUG Imlunestrant
- DRUG LOXO-783
- DRUG Anastrozole, Exemestane, or Letrozole
Study Locations (20)
Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
- UT Southwestern Medical Center - Dallas
- University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
California
- UCLA Medical Center - Los Angeles
- UCSF Medical Center at Mission Bay - San Francisco
- Stanford University Hospital - Stanford
Other
- Cancer Research SA - Adelaide
- Peter Maccallum Cancer Institute Erb - East Melbourne
- St Vincent's Hospital - Sydney
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
- Wilmot Cancer Institute - Rochester
Arizona
- Mayo Clinic of Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville
Georgia
- Winship Cancer Center Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT05307705 still lists
NCT05307705 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fulvestrant is the first listed.
NCT05307705 names 20 study sites across 11 states, led by Texas, California, Other.
Frequently Asked Questions
What is clinical trial NCT05307705 about?
NCT05307705 is a clinical study titled "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors". The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and...
What is the current status of trial NCT05307705?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2022-05-11. Estimated completion is 2026-12.
What conditions does trial NCT05307705 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05307705?
The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG), Imlunestrant (DRUG), LOXO-783 (DRUG), Anastrozole, Exemestane, or Letrozole (DRUG).
Who is sponsoring clinical trial NCT05307705?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05307705 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05307705's enrollment target sits among peer trials
193 389th of 1224 higher than 836 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI